申请人:Hamanaka S. Ernest
公开号:US20050228015A1
公开(公告)日:2005-10-13
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
本发明涉及取代杂环和苯基磺酰胺化合物,含有这些化合物的制药组合物以及将这些化合物用作过氧化物酶增殖子激活受体(PPAR)激动剂。PPARα激动剂,含有这些化合物的制药组合物以及使用这些化合物以提高某些血浆脂质水平,包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酯,从而治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病,如动脉粥样硬化和心血管疾病,在哺乳动物,包括人类中。这些化合物还可用于治疗反能量平衡(NEB)和反刍动物相关疾病。